Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Oklahoma for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Oklahoma only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Oklahoma (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ali Moussa (NPI 1548207814)

Field	Value
Entity Type	Individual
Organization	Ali Moussa
Address	12697 E 51st St
City	Tulsa
State	OK
ZIP	74146
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 2, 2006

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

Payer mix and scale: This provider is effectively single-payer in the datasets provided, with $1.6M in lifetime Medicare revenue and no Medicaid billing on file (none). That concentration means Medicare policies and fee schedules drive the practice’s revenue and utilization profile rather than dual-payer dynamics.

Revenue concentration around immunotherapy and imaging: The top three Medicare codes — J9271, J9299, and 78815 — together account for 60.9% of this provider’s Medicare revenue. J9271 produced $490.2K (33.0% of total Medicare revenue), J9299 produced $266.6K (17.9%), and 78815 produced $148.8K (10.0%), indicating heavy reliance on high-cost oncology infusions and PET/CT imaging.

Service-line implications — medical oncology with integrated imaging: The code mix is consistent with a medical oncology practice that delivers immunotherapy (pembrolizumab J9271 and nivolumab J9299), administers chemotherapy (96413) and supportive biologics (e.g., J1449, J0897), and orders advanced diagnostic imaging (78815, 78816, A9552). This combination suggests the practice manages active systemic cancer care and coordinates PET/CT imaging rather than functioning solely as a consult or palliative clinic.

Competitive standing on flagship drugs and imaging: Volume for J9271 and J9299 is modest relative to national peers — J9271 at the 44th percentile and J9299 at the 40th percentile are described as typical, unremarkable volumes — while 78815 sits at the 78th percentile (typical, unremarkable). In other words, this provider is not a dominant national player for these high-cost immunotherapies but does appear to use PET/CT imaging at above-average levels compared with many peers.

High outpatient visit and ancillary procedural intensity: The provider is an outlier on evaluation-and-management volume for established patients — 99214 is labeled an "extreme outlier, far above typical national volume for this code" (rank reflecting the 98th percentile), and related E&M codes (99213, 99204, 99205) also appear at high national percentiles. This pattern indicates a heavy throughput of clinic-based management and follow-up visits, which complements ongoing infusion and imaging activity.

Ancillary diagnostic and procedure footprint: Multiple diagnostic/lab and radiation-delivery codes appear with meaningful revenue shares — examples include 78815 ($148.8K, 10.0% of Medicare revenue), A9552 ($19.4K), and radiation delivery codes such as G6015 ($58.9K) and G6012. The presence of these codes suggests the practice coordinates or provides access to advanced imaging and some radiation service delivery components, creating bundled utilization around systemic oncology care.

Operational tenure and potential implications: The provider’s NPI was enumerated on 2006-06-02 (~20 years ago), indicating a long-tenured practice presence. That tenure can reflect an established referral base and operational experience managing complex oncology regimens, which may influence payer contracting and network planning decisions.

Risk and opportunity considerations for payers: Given the concentration of revenue in expensive immunotherapies and imaging (60.9% of Medicare revenue from the top three codes) and the absence of Medicaid claims, payers should prioritize review of site-of-care, drug acquisition/pricing, and imaging utilization policies when assessing value and managing spend for this clinician. The unusually high E&M volume for 99214 may also warrant evaluation of visit complexity and case-mix documentation as part of utilization management and network strategy discussions.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

75 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,400	$40	$490.2K
J9299	Injection, nivolumab, 1 mg	12,120	$20	$266.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	150	$1,030	$148.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,140	$90	$99K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,900	$30	$72.6K
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	230	$250	$58.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$90	$38.6K
J0897	Injection, denosumab, 1 mg	1,560	$20	$29.6K
J3490	Unclassified drugs	130	$230	$29.1K
J1439	Injection, ferric carboxymaltose, 1 mg	26,250	$1	$26.3K

Showing 1–10 of 75

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Oklahoma Distribution

Ali Moussa — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Oklahoma

Full comparison — all codes billed, vs. state median

75 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	10	10,600	$40	$466.9K
J9299	7	10	14,050	$20	$324.4K
G6015	9	10	270	$250	$141K
J0897	50	70	2,130	$20	$91.2K
J1449	5	10	3,040	$30	$78.5K
J1627	9	10	6,100	$1	$30.1K
G6012	6	10	180	$160	$30K
78815	24	80	80	$230	$29.2K
77014	28	40	500	$50	$29.2K
96413	13	60	210	$90	$26.4K

Showing 1–10 of 75

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ali Moussa, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Grenville Jones	ME	Therapeutic Radiology Physician	$2.8M	$0
Scott Cole	OK	Hematology & Oncology Physician	$2.3M	$0
Charles Taylor	OK	Hematology & Oncology Physician	$2.3M	$0
Mark Olsen	OK	Hematology & Oncology Physician	$2.2M	$0
Paul Zito	OK	Hematology & Oncology Physician	$2.2M	$0
Melinda Dunlap	OK	Hematology & Oncology Physician	$2.1M	$0
Mark Jennings	TX	Internal Medicine Physician	$2.1M	$0
Oklahoma Cancer Specialists And Research Institute LLC	OK	Hematology & Oncology Physician	$0	$1.7M
Caleb Scheckel	OK	Hematology & Oncology Physician	$1.6M	$0
Leslie Yonemoto	OK	Radiation Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as Ali Moussa, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Option 1 Nutrition Solutions LLC	OK	Durable Medical Equipment & Medical Supplies	$0	$18.8M
Regional Medical Laboratory, Inc	OK	Clinical Medical Laboratory	$0	$17.6M
Labcorp Oklahoma, Inc.	OK	Clinical Medical Laboratory	$6.8M	$7.8M
Access Pain Solutions	OK	Pain Medicine Physician	$0	$13.1M
Osu Center For Health Sciences	OK	Medical Specialty Clinic/Center	$0	$10.5M
Advanced Pediatric Care	OK	Durable Medical Equipment & Medical Supplies	$0	$4.9M
Asm LLC	OK	Customized Equipment (DME)	$0	$4.7M
Pathology Laboratory Associates, Inc.	OK	Anatomic Pathology & Clinical Pathology Physician	$22.2K	$3.9M
Sleep Management, L.L.C.	OK	Oxygen Equipment & Supplies (DME)	$0	$3.6M
Tulsa Bone & Joint Associates PC	OK	Orthopaedic Surgery Physician	$0	$3M

Ali Moussa — Billing Profile & Reimbursement Data

Sign up for Ali Moussa — Billing Profile & Reimbursement Data policy alerts

Ali Moussa — Billing Profile & Reimbursement Data

Sign up for Ali Moussa — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References